Clinical-stage biotechnology company developing targeted protein degradation (TPD) cancer therapeutics using its proprietary Degraducer® platform
Clinical-stage biotechnology company developing targeted protein degradation (TPD) cancer therapeutics using its proprietary Degraducer® platform. Its pipeline includes targeted and immuno-oncology programs, including BTK and SHP2 degraders, and an androgen receptor degrader program licensed to Yuhan.